ARCHIVES

ODAC Recommends Femara Campath For FDA Approval.

This article is from The Cancer Letter archive.

Vol. 27 No. 01 | January 5, 2001

Download PDF Visit The Full Archive

Related Articles

NCCN Guidelines Retain Avastin For Breast Cancer

October 22, 2010

Grassley Seeks Data On Sponsored Travel By NCI Scientists

October 29, 2010

NIH Defines Misconduct

December 9, 1994

Estrogen-Only HRT Little Risk In Endometrial Cancer, GOG Study Indicates

March 26, 2004

Letters From Ovarian Cancer Survivors Shed Light On Their Psychological Distress

October 31, 2003

14th Cancer Congress Big Success; CICA Satellite Established; US, USSR Renew Cancer Agreement

September 12, 1986